Chief Business Executive, BeiGene
Angus joined BeiGene in July 2020 as Chief Business Executive, responsible for Corporate Strategy, Product Strategy and Valuation, Clinical and Business Development Insights, Search and Evaluation, Transactions, Alliance Management and Investing.
Previously, Angus was the CEO of the Dementia Discovery Fund (DDF). Prior to the DDF, he spent 12 years at Celgene at various roles including VP of North American and European Regulatory Affairs and Corporate VP of Business Development and Alliance Management. Angus previously worked at Novartis Oncology, Merck KGaA, Rhone Poulanc-Rohrer, SmithKline Beecham, and the US Food and Drug Administration. Outside of BeiGene, Angus currently serves as Chair of the Board of Toronto Innovation Acceleration Partners.
Angus received his undergraduate degree from the University of Richmond, his Ph.D. in Anatomy & Immunology from the Medical College of Virginia and completed his post-doc at the National Cancer Institute.